Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.23.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Total revenue $ 678 $ 426 $ 1,725 $ 796
Costs of revenue 117 89 339 235
Gross profit 561 337 1,386 561
Operating expenses:        
Research and development 2,525 1,523 6,889 4,651
General and administrative 990 1,069 3,313 2,918
Sales and marketing 259 291 877 1,023
Grant and contract expenses 401 247 942 423
Total operating expenses 4,175 3,130 12,021 9,015
Loss from operations (3,614) (2,793) (10,635) (8,454)
Other income (expenses):        
Interest expense (4) (2) (12)
Interest income 33 5 117 8
Gain (loss) on disposal of assets 17 17 (1)
Change in fair value of derivative liabilities 374 60 5,344 208
Offering costs of derivative liabilities (786)
Other income, net 8 7 170
Total other income (expense), net 424 69 4,697 373
Net loss before income taxes (3,190) (2,724) (5,938) (8,081)
Provision for income taxes
Net loss (3,190) (2,724) (5,938) (8,081)
Deemed dividend related to convertible preferred stock (26)
Net loss attributable to common stockholders $ (3,190) $ (2,724) $ (5,964) $ (8,081)
Net loss per share – basic and diluted        
Basic – net loss $ (0.76) $ (11.02) $ (1.68) $ (32.69)
Basic – deemed dividend on conversion of preferred stock (0.01)
Basic – attributable to common stockholders (0.76) (11.02) (1.69) (32.69)
Diluted – net loss (0.81) (11.10) (3.03) (33.04)
Diluted - deemed dividend on conversion of preferred stock (0.01)
Diluted – attributable to common stockholders $ (0.81) $ (11.10) $ (3.04) $ (33.04)
Weighted average common shares outstanding:        
Basic 4,208,069 247,248 3,524,174 247,179
Diluted 4,399,269 250,870 3,528,301 250,841
Product [Member]        
Total revenue $ 168 $ 173 $ 643 $ 354
Grant and Contract [Member]        
Total revenue $ 510 $ 253 $ 1,082 $ 442